Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ashraf M, Souka A, Adelman R, Forster SH . Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye; e-pub ahead of print 26 August 2016; doi:10.1038/eye.2016.174.
Wood EH, Karth PA, Moshfeghi DM, Leng T . Short-term outcomes of aflibercept for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab. Ophthalmic Surg Lasers Imaging Retina 2015; 46 (9): 950–954.
Rahimy E, Shahlace A, Ali Khan M, Ying GS, Maguire JI, Ho AC et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016; 164 (4): 118–127.
Grover S, Murthy RK, Brar VS, Chalam KV . Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 2009; 148 (2): 266–271.
Călugăru D, Călugăru M . Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016; 168 (8): 290–291.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
Both the authors (DC and MC) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.
Rights and permissions
About this article
Cite this article
Călugăru, D., Călugăru, M. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 31, 342 (2017). https://doi.org/10.1038/eye.2016.238
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.238
